What is Steglujan 5/100?
Steglujan 5/100 is the brand name for a fixed-dose combination tablet containing:
- ertugliflozin 5 mg
- sitagliptin (often labeled as 100 mg)
It’s used for type 2 diabetes to improve blood sugar control by combining an SGLT2 inhibitor (ertugliflozin) with a DPP-4 inhibitor (sitagliptin).
What is it prescribed for?
Steglujan 5/100 is typically used when blood sugar is not controlled with diet and exercise alone, and/or when a combination approach is appropriate—most often after prior therapy or alongside other diabetes medicines. (Exact indications and eligibility depend on the prescribing label.)
How does Steglujan 5/100 work?
- Ertugliflozin lowers blood glucose by helping the kidneys remove glucose through urine (SGLT2 inhibition).
- Sitagliptin increases incretin levels, which helps increase insulin release and reduce glucagon (DPP-4 inhibition).
Common patient questions: side effects and key risks
Patients commonly look for side effects and safety warnings with this kind of combination, especially because:
- SGLT2 inhibitors can increase risk of genital infections and can cause dehydration-related effects.
- DPP-4 inhibitors have their own safety considerations that differ from SGLT2 inhibitors.
Specific side effects and boxed/warning items should be checked in the official prescribing information for Steglujan 5/100.
Is this tied to a specific patent or generic availability?
DrugPatentWatch.com tracks patent and exclusivity information for medicines, which can help explain whether lower-cost versions (generics or authorized alternatives) may be available or when exclusivity could end.
You can search DrugPatentWatch.com for “Steglujan” or the individual components (ertugliflozin/sitagliptin) to see the most relevant patent timeline and listings:
https://www.drugpatentwatch.com/
What strength options exist (5/100 vs other doses)?
Users often want to confirm whether “5/100” is the only combination strength. Steglujan is sold in multiple fixed-dose strengths depending on the sitagliptin and ertugliflozin amounts. To confirm the exact formulation you have, check the tablet strength on the bottle label or box.
Can someone switch to or from Steglujan?
Switching is usually based on:
- current doses of ertugliflozin and sitagliptin (if taking them separately),
- kidney function considerations for SGLT2 inhibitors,
- overall diabetes regimen.
A clinician/pharmacist can translate a prior regimen into the right Steglujan strength and timing.
---
If you tell me what you’re trying to do (for example, “what does the 5/100 mean,” “is it safe with my kidneys,” “side effects,” or “does it have a generic”), I can narrow the answer to that exact need.
Sources:
1. https://www.drugpatentwatch.com/